- Home
- PENN vs RARE Comparison
PENN vs RARE Comparison
Compare PENN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- RARE
- Stock Information
- Founded
- PENN 1972
- RARE 2010
- Country
- PENN United States
- RARE United States
- Employees
- PENN N/A
- RARE N/A
- Industry
- PENN Hotels/Resorts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- PENN Consumer Discretionary
- RARE Health Care
- Exchange
- PENN Nasdaq
- RARE Nasdaq
- Market Cap
- PENN 2.8B
- RARE 3.2B
- IPO Year
- PENN 1994
- RARE 2014
- Fundamental
- Price
- PENN $16.46
- RARE $34.60
- Analyst Decision
- PENN Buy
- RARE Strong Buy
- Analyst Count
- PENN 16
- RARE 13
- Target Price
- PENN $22.80
- RARE $87.69
- AVG Volume (30 Days)
- PENN 3.3M
- RARE 1.3M
- Earning Date
- PENN 11-06-2025
- RARE 11-04-2025
- Dividend Yield
- PENN N/A
- RARE N/A
- EPS Growth
- PENN N/A
- RARE N/A
- EPS
- PENN N/A
- RARE N/A
- Revenue
- PENN $6,745,700,000.00
- RARE $610,159,000.00
- Revenue This Year
- PENN $8.36
- RARE $19.65
- Revenue Next Year
- PENN $5.50
- RARE $23.35
- P/E Ratio
- PENN N/A
- RARE N/A
- Revenue Growth
- PENN 7.33
- RARE 26.77
- 52 Week Low
- PENN $13.25
- RARE $25.81
- 52 Week High
- PENN $23.08
- RARE $53.47
- Technical
- Relative Strength Index (RSI)
- PENN 38.29
- RARE 59.78
- Support Level
- PENN $16.25
- RARE $33.94
- Resistance Level
- PENN $18.28
- RARE $35.95
- Average True Range (ATR)
- PENN 0.57
- RARE 1.33
- MACD
- PENN -0.02
- RARE 0.10
- Stochastic Oscillator
- PENN 10.37
- RARE 70.07
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.